Cellectis schedules annual general meeting for June 27, 2023
Biotechnology firm Cellectis will hold its annual general meeting in Paris on June 27, 2023, to address company governance matters.
Cellectis, a clinical-stage biotechnology company focused on gene-editing therapies, has scheduled its annual general meeting for June 27, 2023. The event will take place at the Biopark auditorium in Paris, France, commencing at 2:30 p.m. CET.
During the meeting, shareholders will review items outlined in the official agenda. As a publicly traded entity on both Euronext Growth and Nasdaq, the firm is required to conduct these meetings to maintain regulatory compliance and facilitate communication between the board and its investors.
Interested parties can access the convening notice, which includes the full agenda and instructions for participation, via the company’s investor relations portal. The meeting remains a standard procedural event for the company, which continues to develop its gene-editing platform for cell and gene therapy applications.